BioCryst’s BCX4430 antiviral shows promise in Ebola-infected monkeys
Undertaken at the US Army Medical Research Institute of Infectious Diseases (USAMRIID), the proof-of-concept study was focused on assessing the effect of BCX4430 treatment on survival through day